On November 5, SKB BIO recorded an Intraday Rise of 3.16% in Regular Trading, with the stock trading at HK$469.0 and turnover of HK$124 million.
The clearest recent catalyst is the company’s disclosure that it subscribed to two bank structured deposits totaling 12 billion yuan, including 5 billion yuan with Zheshang Bank and 7 billion yuan with Bank of China, using idle internal funds.
The company stated the products are principal-protected with floating returns and medium-to-short tenor, intended to improve capital efficiency, while no IPO or placement proceeds were used. The announcement also constituted two disclosable transactions, and the latest market reaction suggests investors viewed the move as reflecting relatively strong cash availability rather than a change in operating fundamentals. Earlier positive clinical and filing progress for sac-TMT remains part of the broader backdrop for sentiment.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments